HYBIO(SZ:300199) Xin Lang Zheng Quan·2025-10-09 01:21Group 1 - On September 30, Hanyu Pharmaceutical's stock increased by 1.52%, with a trading volume of 689 million yuan [1] - The financing data shows that on the same day, Hanyu Pharmaceutical had a financing purchase amount of 70.21 million yuan and a financing repayment of 93.34 million yuan, resulting in a net financing outflow of 23.13 million yuan [1] - As of September 30, the total balance of margin trading for Hanyu Pharmaceutical was 1.291 billion yuan, accounting for 6.85% of its market capitalization, which is above the 80th percentile level over the past year [1] Group 2 - As of June 30, the number of shareholders of Hanyu Pharmaceutical was 63,000, an increase of 9.95% compared to the previous period [2] - For the first half of 2025, Hanyu Pharmaceutical achieved an operating income of 549 million yuan, a year-on-year increase of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a year-on-year increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends distributed in the last three years [2]